Watson confirms Actavis acquisition in deal set to take group revenues to $8bn this year
This article was originally published in Scrip
With an upfront payment of €4.25 billion ($5.6 billion) and up to €250 million in future common stock to acquire the private Swiss firm Actavis Group, Watson Pharmaceuticals is now the third largest global generics company with anticipated 2012 pro forma revenues of $8 billion.
You may also be interested in...
Allergan was expected to announce soon that it would follow its shareholders' advice and split the company in two, but it's being acquired by AbbVie for $63bn instead, finally giving investors a big boost in their Allergan holdings after years of decline.
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
As Takeda pays down debt associated with the acquisition of Shire and advances R&D programs toward global filings, the company is selling its growth plan to investors – but are they buying?